SLC6A3 and attention deficit-hyperactivity disorder: Since the current stimulant treatments (e.g. methylphenidate) for ADHD all strengthen synaptic dopamine signaling [39], we examined the effects of the TAT-DATNT on the hyperactivity of SHR rats and we hypothesized that this peptide will reverse such hyperactivity by disrupting the D2R-DAT interaction.